---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023175"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:28:38.996450+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027

## Summary
- Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.
- Initiated Phase 3 ECLIPSE registrational program for chronic hepatitis delta; first patient enrolled March 2025.
- Cash and investments ~$1.02B, down $75.6M in Q1; cash runway into mid-2027.
- Alnylam opted out of profit-sharing for elebsiran in CHB/CHD; Vir seeking partner for CHB development.
- Dose escalation ongoing for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA); Phase 1 for VIR-5525 (EGFR) planned Q2 2025.

## SEC filing metadata
- accession: 0001628280-25-023175
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025023175/0001628280-25-023175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025023175/vir-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023175
- JSON: https://secwatch.observer/filing/0001628280-25-023175.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.